



The DOJ Withdraws from the Health Care Antitrust Statements: a Cause for Concern for Physician Organizations?

April 6, 2023

Thomas J. Babbo
thomas.babbo@hmbr.com

John P. Marren
jpm@hmbr.com

Clinical Integration, Risk, and Accountable Care: New developments from the DOJ




On February 3, 2023, *the Department of Justice (“DOJ”) withdrew from three antitrust policy statements* (collectively, the “Statements”) that it had previously jointly promulgated with the Federal Trade Commission (“FTC”). The DOJ’s withdrawal from the Statements – which it now characterizes as “overly permissive” and “out of date” – *puts an end to a suite of “safety zones” vis-à-vis DOJ antitrust enforcement in health care.*

Until the DOJ’s February announcement, these safety zones assured health care organizations that if they met set criteria when engaging in certain types of joint conduct, DOJ would (absent exceptional circumstances) view the conduct as legitimate and pro-competitive.

The 1993 Antitrust Enforcement Policy Statements in the Health Care Area. The 1993 Statements were the first policy statement by the agencies to provide antitrust safety zones for circumstances under which the Department of Justice and the Federal Trade Commission would not challenge, absent extraordinary circumstances: hospital mergers, hospital joint ventures involving high-technology or other expensive medical equipment, physicians' provision of information to purchasers of health care services; hospital participation in exchanges of price and cost information; joint purchasing arrangements among health care providers; and physician network joint ventures. In 1994, the agencies expanded the scope of the 1993 Statements to include joint ventures involving expensive services.


Notably, the 1993 Statements and their expansion in 1994 only discussed the bearing of substantial financial risk in the context of conduct that physician networks could undertake without violating antitrust law – and established a safety zone for such physician networks that comprised only 20% of any particular medical or surgical specialty in a geographic market.



Statement 8 of the 1996 guidance provided much more expansive advice for physician joint ventures seeking to avoid per se illegal treatment.

The 1996 Statements:

- reiterated the 1993 safety zones for independent practice associations (IPAs) and physician hospital organizations (PHOs) that share substantial financial risk;
- described appropriate “messenger model” contracting by IPAs and PHOs; and
- articulated, using traditional antitrust “rule-of-reason” analysis, how an IPA or PHO could create significant efficiencies through clinical integration that could outweigh the restraint on trade that joint payor contracting would otherwise entail.




The 2011 Statement established that the agencies would not challenge as per se illegal a qualified ACO participating the MSSP that jointly negotiates with commercial payors. Instead, the DOJ and FTC would apply a “rule of reason” analysis.

Additionally, the 2011 Statement established a safety zone for ACOs with participants that hold combined share of less than 30 percent of a “common service” (i.e., services in the same medical or surgical specialty or particular inpatient or ambulatory services) in each participant’s primary service area (PSA) as defined by Medicare.

The issuance of the 2011 Statement led to the widespread, and erroneous, view that ACOs in the MSSP were “deemed” clinically integrated or received a new antitrust “exemption.”

In point of fact, the “rule of reason” treatment of ACOs advocated in the 2011 Statement would actually require the same analysis described in the 1996 Statements of whether the quality, cost, and access efficiencies created by the ACO would outweigh the restraint on trade caused by joint contracting and whether joint contracting is reasonably necessary to achieve those efficiencies.

And, in any event, the analysis of efficiencies would only apply to those providers (almost exclusively primary care physicians) who are actively involved in the quired by the MSSP, and only when those are applied specifically to the populations contracted under commercial payor contracts.



Remaining legal guidance for physician organizations



FTC Advisory Opinions



Suburban Health Organization



FTC/DOJ Policy Statements



FTC Enforcement Actions



DOJ's withdrawal from the Health Care Statements: key takeaways



The DOJ is indicating a ***much more robust posture in enforcement*** of antitrust in the health care industry.

Well-established Supreme Court precedent regarding ***the “rule-of-reason” remains the law of the land***. This means that financially and clinically integrated physician organizations need to ***demonstrate efficiencies in quality, cost, and access*** – and show how ***collective contracting with payors is reasonably necessary*** to achieve these efficiencies.

Health systems and physician organizations ***should examine the extent of their reliance of the safety zones*** contained in the Statements (particularly in the area of information sharing and joint purchasing) and should ***take the opportunity to reassess their antitrust risk regardless*** of their application of the safety zones.

Moreover, ***health care organizations must understand that establishing an ACO for participation in the MSSP decidedly does not result in automatic consideration as a “clinically integrated” network*** – and ACOs engaged in contracting with commercial payors ***cannot*** rely on the 2011 Statement to ward off DOJ scrutiny.



Thomas J. Babbo

thomas.babbo@hmbr.com

John P. Marren

jpm@hmbr.com

161 N. Clark Street, Suite 1700

Chicago, Illinois 60601

312.946.1800

www.hmbr.com